• In order to investigate their effects in

  2025-02-05

  

  In order to investigate their effects in vitro, therefore, we first used TE671 cells, which have provided a useful source of human AChR for in vitro and radioimmunoassay studies. We found no marked effect of either MuSK-MG or SNMG sera on AChR numbers or on AChR subunit expression. This appears to c

• Introduction Myasthenia gravis MG is an

  2025-02-05

  

  Introduction Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness, which is mainly due to autoantibodies reducing the number or function of postsynaptic formula for sodium fluoride receptors (AChRs) [1], [2]. Animal models have been developed to uncover the immunopatho

• As also found by Stolarski et al inclusion of N

  2025-02-05

  

  As also found by Stolarski et al. [14], inclusion of N2O in the model is successful in reducing the effect of dynamics [13] in the lower stratosphere in the Northern Hemisphere (30–60°N in our case). The inclusion of N2O also decreased the error bars on the trend values, but the trend values still c

• chpg Additional evidence for a putative role of COXs

  2025-02-05

  

  Additional evidence for a putative role of COXs and 5-LOX in AD derives from pharmacological studies using inhibitors of these enzymes (for review, see Firuzi and Praticò, 2006). In addition to helping delineate the pathobiological mechanisms of AD, these results raise hope for discovering novel the

• br Introduction Nausea and vomiting are

  2025-02-05

  

  Introduction Nausea and vomiting are among the most distressing side effects associated with chemotherapy in cancer patients (Billio et al., 2010). Severe emesis can negatively affect a patient's nutritional state, ability to work and motivation, which can, in turn, interfere with the clinical co

• PF also a dual Aurora A and Aurora

  2025-02-03

  

  PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly DiscoveryProbe™ Natural Product Library for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-

• It has also been reported that defects

  2025-02-03

  

  It has also been reported that defects in ATM or ATR signalling are synthetically lethal with PARP inhibition (Turner et al., 2008, Peasland et al., 2011, Yap et al., 2011, Michels et al., 2014), suggesting that combined inhibition of PARP and ATM or ATR may be an effective therapeutic strategy. In

• cy5 dye To better illustrate the involved neuronal

  2025-02-03

  

  To better illustrate the involved neuronal postganglionic pathways, central apelin-13 injection was performed in rats received peripheral preadministration of NOS inhibitor L-NAME, sympatholytic agent guanethidine and/or muscarinic receptor agonist bethanechol. Compared with the rats received vehicl

• Available data thus indicate that there

  2025-02-03

  

  Available data thus indicate that there are at least two ways that HMGA proteins can induce localized changes in the chromatin structure of inducible gene promoters, both of which involve positioned nucleosomes that must be “remodeled” before gene transcription can occur. The first mechanism is exem

• The beneficial treatment with several statins have been eval

  2025-02-01

  

  The beneficial treatment with several statins have been evaluated in AD patients (Kivipelto et al., 2005), with controversial results. It has been suggested that statins slow cognitive decline in mild to moderate AD (Miida et al., 2005). Treatment with atorvastatin, combined with other medications,

• br Theoretical mechanism of ABCA activity in

  2025-02-01

  

  Theoretical mechanism of ABCA2 activity in LE/LY in modulation of cholesterol trafficking It is important to confirm that ABCA2 is a lipid transporter and identify the substrates that are mechanistic in its cholesterol sequestering activity. We hypothesize that ABCA2 modulates cholesterol sequest

• br Conflict of Interest br Transparency Document

  2025-02-01

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• br Concluding Remarks The effects of point mutations of the

  2025-02-01

  

  Concluding Remarks The effects of point mutations of the four ARs on ligand binding affinities, functional potencies, and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allow

• AdipoRon is an orally active synthetic

  2025-02-01

  

  AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r

• Our current knowledge on autophagy broadly

  2025-02-01

  

  Our current knowledge on autophagy broadly differentiates it into three types: macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy mainly involves the sequestration of cytoplasmic contents in a double-walled membrane followed by the fusion with the lysosomes. The lysosom

14209 records 16/948 page Previous Next First page 上5页 1617181920 下5页 Last page